Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 U.S. Surveillance Study

Clinics in Laboratory Medicine

Volumn 24, Issue 2, 2004, Pages 503-530

  Jacobs, Michael R ^a   Bajaksouzian, Saralee ^a   Windau, Anne ^a   Good, Caryn E ^a   Lin, Gengrong ^b   Pankuch, Glenn A ^b   Appelbaum, Peter C ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAMASE; CEFACLOR; CEFDINIR; CEFIXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME AXETIL; CLARITHROMYCIN; CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 2942625981     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2004.03.008     Document Type: Review

References (65)

1. Black S.B., Shinefield H.R. Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine on a large health maintenance organization population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. The Kaiser Permanente Pediatric Vaccine Study Group. Pediatr Infect Dis J. 11:(8):1992;610-613
2. Whitney C.G., Farley M.M., Hadler J., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 348:(18):2003;1737-1746
3. Khan W., Ross S., Rodriguez W., Controni G., Saz A.K. Haemophilus influenzae type B resistant to ampicillin. A report of two cases. JAMA. 229:(3):1974;298-301
4. Tomeh M.O., Starr S.E., McGowan J.E. Jr., Terry P.M., Nahmias A.J. Ampicillin-resistant Haemophilus influenzae type B infection. JAMA. 229:(3):1974;295-297
5. Doern G.V., Jorgensen J.H., Thornsberry C., et al. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae. Antimicrob Agents Chemother. 32:(2):1988;180-185
6. Rittenhouse S.F., Miller L.A., Kaplan R.L., Mosely G.H., Poupard J.A. A survey of beta-lactamase-producing Haemophilus influenzae. An evaluation of 5750 isolates. Diagn Microbiol Infect Dis. 21:(4):1995;223-225
7. Jones R.N., Jacobs M.R., Washington J.A., Pfaller M.A. A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States. Diagn Microbiol Infect Dis. 27:(3):1997;75-83
8. Jacobs M.R., Bajaksouzian S. Microbiologic evaluation of contemporary Haemophilus influenzae isolates having elevated MICs to amoxicillin-clavulanic acid. Diagn Microbiol Infect Dis. 28:1997;105-112
9. Doern G.V., Brueggemann A.B., Pierce G., Holley H.P. Jr., Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase- positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother. 41:(2):1997;292-297
10. Thornsberry C., Ogilvie P., Kahn J., Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis. 29:(4):1997;249-257
11. Ubukata K., Shibasaki Y., Yamamoto K., et al. Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother. 45:(6):2001;1693-1699
12. Hasegawa K., Yamamoto K., Chiba N., et al. Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States. Microb Drug Resist. 9:(1):2003;39-46
13. Jacobs M.R., Felmingham D., Appelbaum P.C., Gruneberg R.N., Alexander Project G. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 52:(2):2003;229-246
14. Jacobs M.R., Appelbaum P.C. Antibiotic-resistant pneumococci. Rev Med. Microbiol. 6:1995;77-93
15. Bradley J.S., Connor J.D. Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. Pediatr Infect Dis J. 10:(11):1991;871-873
16. Sloas M.M., Barrett F.F., Chesney P.J., et al. Cephalosporin treatment failure in penicillin- and cephalosporin- resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J. 11:(8):1992;662-666
17. Scott-Levin I. Physician drug and diagnosis audit (PDDA). 1997;PMSI Scott-Levin, Inc. Newton, PA
18. Green M., Wald E.R. Emerging resistance to antibiotics: impact on respiratory infections in the outpatient setting. Ann Allergy Asthma Immunol. 77:(3):1996;167-173. quiz 173-5
19. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 26:(1):1998;1-10. quiz 11-2
20. Dagan R., Abramson O., Leibovitz E., et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr Infect Dis J. 15:(11):1996;980-985
21. Dagan R., Abramson O., Leibovitz E., et al. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis. 176:(5):1997;1253-1259
22. Dagan R., Piglansky L., Yagupsky P., Fliss D.M., Lieberman A., Leibovitz E. Bacteriologic response in acute otitis media (AOM): comparison between azithromycin (AZ), cefaclor (CEC) and amoxicillin (AMOX). Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstr. No. K-103:345. 1997;American Society for Microbiology, Washington, DC
23. Craig W.A., Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 15:(3):1996;255-259
24. Drusano G.L., Goldstein F.W. Relevance of the Alexander Project: pharmacodynamic considerations. J Antimicrob Chemother. (38 Suppl A):1996;141-154
25. Drusano G.L., Craig W.A. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother. 9:(Suppl 3):1997;38-44
26. Nightingale C.H. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J. 16:(4):1997;438-443
27. Preston S.L., Drusano G.L., Berman A.L., et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 279:(2):1998;125-129
28. Jacobs M.R., Bajaksouzian S., Zilles A., Lin G., Pankuch G.A., Appelbaum P.C. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob Agents Chemother. 43:(8):1999;1901-1908
29. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A4. 1997;National Committee for Clinical Laboratory Standards, Villanova (PA)
30. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; thirteenth informational supplement: M100-S13. 2003;National Committee for Clinical Laboratory Standards, Wayne (PA)
31. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; fourteenth informational supplement: M100-S14. 2004;National Committee for Clinical Laboratory Standards, Wayne (PA)
32. Dowell S.F., Butler J.C., Marcy S.M., Phillips W.R., Gerber M.A., Schwartz B. Principles of judicious use of antimicrobial agents for pediatric upper respiratory tract infections. Pediatrics. 101:1998;163-165
33. Doern G.V., Brueggemann A., Holley H.P. Jr., Rauch A.M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 40:(5):1996;1208-1213
34. Barry A.L., Pfaller M.A., Fuchs P.C., Packer R.R. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother. 38:(10):1994;2419-2425
35. Barry A.L., Fuchs P.C. In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens. Antimicrob Agents Chemother. 39:(1):1995;238-240
36. Barry A.L. Antimicrobial agents for community-acquired respiratory tract infections. Infection. 23:(Suppl 2):1995;S59-S63. discussion S64
37. Bartlett J.G. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices. Semin Respir Infect. 12:(4):1997;329-333
38. Pelton S.I. Defining resistance: breakpoints and beyond implications for pediatric respiratory infection. Diagn Microbiol Infect Dis. 25:(4):1996;195-199
39. Seral C., Van Bambeke F., Tulkens P.M. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother. Jul. 47:(7):2003;2283-2292
40. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 336:(4):1997;243-250
41. Fine M.J. Risk stratification for patients with community-acquired pneumonia. Int J Clin Pract Suppl. (115):2000;14-17
42. Ball P., Baquero F., Cars O., et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother. 49:(1):2002;31-40
43. Dagan R., Klugman K.P., Craig W.A., Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother. 47:(2):2001;129-140
44. Jacobs M.R. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 7:(11):2001;589-596
45. Fendrick A.M., Saint S., Brook I., Jacobs M.R., Pelton S., Sethi S. Diagnosis and treatment of upper respiratory tract infections in the primary care setting. Clin Ther. 23:(10):2001;1683-1706
46. Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J Antimicrob Chemother. 43:(Suppl A):1999;97-105
47. Ross G.H., Hovde L.B., Ibrahim K.H., Ibrahim Y.H., Rotschafer J.C. Comparison of once-daily versus twice-daily administration of cefdinir against typical bacterial respiratory tract pathogens. Antimicrob Agents Chemother. 45:(10):2001;2936-2938
48. Rodvold K.A., Gotfried M.H., Danziger L.H., Servi R.J. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother. 41:(6):1997;1399-1402
49. Lonks J.R., Garau J., Medeiros A.A. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. J Antimicrob Chemother. 50:(Suppl S2):2002;87-92
50. Jacobs M.R. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin Infect Dis. 35:(5):2002;565-569
51. Zhanel G.G., DeCorby M., Noreddin A., et al. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemother. 52:(1):2003;83-88
52. Noreddin A.M., Roberts D., Nichol K., Wierzbowski A., Hoban D.J., Zhanel G.G. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chemother. 46:(12):2002;4029-4034
53. Novelli A., Fallani S., Cassetta M.I., Arrigucci S., Mazzei T. In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin. J Chemother. 14:(6):2002;584-590
54. den Hollander J.G., Knudsen J.D., Mouton J.W., et al. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. Antimicrob Agents Chemother. 42:(2):1998;377-382
55. Jackson M.A., Burry V.F., Olson L.C., Duthie S.E., Kearns G.L. Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr Infect Dis J. 15:(11):1996;1049-1051
56. Reid R. Jr., Bradley J.S., Hindler J. Pneumococcal meningitis during therapy of otitis media with clarithromycin. Pediatr Infect Dis J. 14:(12):1995;1104-1105
57. Vergis E.N., Yu V.L. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host. Semin Respir Infect. 12:(4):1997;322-328
58. Doern G.V. Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: results of a 1992-93 western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group. J Antimicrob Chemother. 38:(Suppl A):1996;59-69
59. Karlowsky J.A., Thornsberry C., Critchley I.A., et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother. 47:(6):2003;1790-1797
60. Joloba M.L., Windau A., Bajaksouzian S., Appelbaum P.C., Hausdorff W.P., Jacobs M.R. Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. Clin Infect Dis. 33:(9):2001;1489-1494
61. Karlowsky J.A., Thornsberry C., Jones M.E., Evangelista A.T., Critchley I.A., Sahm D.F. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis. 36:(8):2003;963-970
62. Jones R.N., Jenkins S.G., Hoban D.J., Pfaller M.A., Ramphal R. In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. Diagn Microbiol Infect Dis. 37:(2):2000;93-98
63. Rosenfeld R.M. An evidence-based approach to treating otitis media. Pediatr Clin North Am. 43:(6):1996;1165-1181
64. Dowell S.F., Butler J.C., Giebink G.S., et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J. 18:(1):1999;1-9
65. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Sinus and Allergy Health Partnership. Otolaryngol Head Neck Surg. 123:(Suppl.):2000;S1-S32